Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone  (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60 to 80 years. The primary objective was the complete metabolic response (CMR) rate at the end of treatment. Seventy-eight of the 80 patients enrolled were included in the efficacy and safety analysis. CMR was achieved in 32 (41%; 95% confidence interval [CI], 30%-52.7%) patients, which was below the prespecified CMR rate of 55% defined as success in the study. The 2-year progression-free survival (PFS) was 42.1% (95% CI, 30.9%-52.8%), and the 2-year overall survival was 59.2% (95% CI, 47.3%-69.3%). The most common toxicities were hematologic and led to treatment discontinuation in 15% of patients. This large prospective and uniform series of AITL treatment data was used to perform an integrative analysis of clinical, pathologic, biologic, and molecular data. TET2, RHOA, DNMT3A, and IDH2 mutations were present in 78%, 54%, 32%, and 22% of patients, respectively. IDH2 mutations were associated with distinct pathologic and clinical features and DNMT3A was associated with shorter PFS. In conclusion, the combination of lenalidomide and CHOP did not improve the CMR in AITL patients. This trial clarified the clinical impact of recurrent mutations in AITL. This trial was registered at www.clincialtrials.gov as #NCT01553786.

[1]  G. Bhagat,et al.  ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY. , 2019, Blood.

[2]  R. Gascoyne,et al.  ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma , 2019, Hematological Oncology.

[3]  J. Vose,et al.  PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS , 2019, Hematological Oncology.

[4]  P. Gaulard,et al.  The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations , 2019, Modern Pathology.

[5]  S. Horwitz,et al.  Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. , 2019, Blood advances.

[6]  P. Gaulard,et al.  Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. , 2018, Blood.

[7]  T. Habermann,et al.  Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials , 2018, Blood Cancer Journal.

[8]  T. Molina,et al.  Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. , 2018, The Lancet. Haematology.

[9]  A. Ferrando,et al.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. , 2018, Cancer cell.

[10]  R. Küppers,et al.  TET2 mutations in B cells of patients affected by angioimmunoblastic T‐cell lymphoma , 2017, The Journal of pathology.

[11]  Thomas Filleron,et al.  Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Gaulard,et al.  Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin , 2017, Haematologica.

[13]  S. Miyano,et al.  Identification of cell-type-specific mutations in nodal T-cell lymphomas , 2017, Blood Cancer Journal.

[14]  P. Gaulard,et al.  The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development , 2016, Proceedings of the National Academy of Sciences.

[15]  Francine E. Garrett-Bakelman,et al.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling , 2016, Nature Medicine.

[16]  Ryan D. Morin,et al.  Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. , 2016, Blood.

[17]  P. Gaulard,et al.  Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  T. Molina,et al.  Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets , 2015, Haematologica.

[19]  A. Evens,et al.  Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. , 2015, Blood.

[20]  T. Reiman,et al.  Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma , 2015, Cancer.

[21]  R. Gascoyne,et al.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Min Kyung Sung,et al.  A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[24]  Federica Fioroni,et al.  Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[26]  O. Nureki,et al.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[27]  M. Mazzei,et al.  Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T‐cell lymphoma: report of a case with long‐term follow‐up , 2013, Hematological oncology.

[28]  B. Coiffier,et al.  A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. , 2013, European journal of cancer.

[29]  J. Maciejewski,et al.  Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. , 2012, Blood.

[30]  N. Harris,et al.  A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[31]  P. Gaulard,et al.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. , 2012, Blood.

[32]  P. Gaulard,et al.  Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA , 2012, Haematologica.

[33]  W. Chan,et al.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[34]  Christian Bastard,et al.  TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.

[35]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[36]  T. Reiman,et al.  Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma , 2010, Cancer.

[37]  P. Gaulard,et al.  Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma , 2010, British journal of haematology.

[38]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Christian Gisselbrecht,et al.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.

[40]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[42]  P. Gaulard,et al.  VJ REARRANGEMENTS OF THE TCRγ LOCUS IN PERIPHERAL T‐CELL LYMPHOMAS: ANALYSIS BY POLYMERASE CHAIN REACTION AND DENATURING GRADIENT GEL ELECTROPHORESIS , 1996, The Journal of pathology.

[43]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.